مجله سلامت و ورزش: رویکردهای نوین (سورن)

Strimbu K, Tavel JA. What are biomarkers? Current Opinion in HIV and AIDS 2010;5:463.

Garrod D, Chidgey M. Desmosome structure, composition and function. Biochim Biophys Acta 2008;1778:572–587.

Thomason HA, Scothern A, McHarg S, Garrod DR. Desmosomes: Adhesive strength and signalling in health and disease. Biochem J 2010;429:419–433.

Spindler V, Waschke J. Desmosomal cadherins and signaling: lessons from autoimmune disease. Cell Commun Adhes 2014;21:77-84.

Huang CC, Lee TJ, Chang PH, Lee YS, Chuang CC, Jhang YJ, et al. Desmoglein 3 is overexpressed in inverted papilloma and squamous cell carcinoma of sinonasal cavity. Laryngoscope 2010;120:26-9.

Amagai M, Stanley JR. Desmoglein as a target in skin disease and beyond. J Invest Dermatol 2012;132:776-84.

Kim J, Beidler P, Wang H, Li C, Quassab A, Coles C, et al. Desmoglein-2 as a prognostic and biomarker in ovarian cancer. Cancer Biol Ther 2020;21:1154-62.

Sun R, Ma C, Wang W, Yang S. Upregulation of desmoglein 2 and its clinical value in lung adenocarcinoma: a comprehensive analysis by multiple bioinformatics methods. Peer J 2020;8:8420.

Zhou BX, Li Y. Significance of desmoglein‐2 on cell malignant behaviors via mediating MAPK signaling in cervical cancer. Kaohsiung J Med Sci 2020;36:336-43.

Ormanns S, Altendorf-Hofmann A, Jackstadt R, Horst D, Assmann G, Zhao Y, et al. Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma. Br J Cancer 2015;113:1460-6.

Barber AG, Castillo-Martin M, Bonal DM, Rybicki BA, Christiano AM, Cordon-Cardo C. Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PLoS One 2014;9:98786.

Lee K, Lee S-H, Kim W, Lee J, Park J-G, Kim J-S, et al. Dsg2-mediated c-Met activation in anaplastic thyroid cancer motility and invasion. Endocr Relat Cancer 2020;27:601-14.

Chen Y, Chang J, Lee L, Wang H, Liao C, Chiu C, et al. DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. Oncogene 2007;26:467-76.

Kouno M, Minabe M, Tachikawa T, Stanley JR. Oral cancer treatment by targeted drug delivery system with an anti-desmoglein monoclonal antibody. J Dermatol Sci 2017;86:27.

Fang W-K, Chen B, Xu X-E, Liao L-D, Wu Z-Y, Wu J-Y, et al. Altered expression and localization of desmoglein 3 in esophageal squamous cell carcinoma. Acta Histochem 2014;116:803-9.

Wong MP, Cheang M, Yorida E, Coldman A, Gilks CB, Huntsman D, Berean K. Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients. Pathology 2008;40:611-6.

Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin Med Insights Cardiol 2014;8:CMC.17067.

Chen D, Wirth KM, Kizy S, Muretta JM, Markowski TW, Yong P, et al. Desmoglein 2 functions as a receptor for fatty acid binding protein 4 in breast cancer epithelial cells. Mol Cancer Res 2023:1-13.

Cai F, Zhu Q, Miao Y, Shen S, Su X, Shi Y. Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2. J Cancer Res Clin Oncol 2017;143:59-69.

Brown L, Wan H. Desmoglein 3: a help or a hindrance in cancer progression? Cancers 2015;7:266-86.

Wan H, Teh M-T, Mastroianni G, Ahmad US. Comparative transcriptome analysis identifies Desmoglein-3 as a potential oncogene in oral cancer cells. Cells 2023;12:2710.

Montenegro JD. Gene co-expression network analysis. Plant bioinformatics: methods and protocols: Springer; 2022. p. 387-404.

Burks HE, Pokorny JL, Koetsier JL, Roth-Carter QR, Arnette CR, Gerami P, et al. Melanoma cells repress Desmoglein 1 in keratinocytes to promote tumor cell migration. J Cell Biol 2023;222:202212031.

Xin Z, Yamaguchi A, Sakamoto K. Aberrant expression and altered cellular localization of desmosomal and hemidesmosomal proteins are associated with aggressive clinicopathological features of oral squamous cell carcinoma. Virchows Arch 2014;465:35-47.

Jiang R, Shi Z, Johnson JJ, Liu Y, Stack MS. Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma. J biol Chem 2011;286:9127-35.

Overmiller AM, Pierluissi JA, Wermuth PJ, Sauma S, Martinez-Outschoorn U, Tuluc M, et al. Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes. FASEB J 2017;31:3412.

Minabe M, Akiyama Y, Higa K, Tachikawa T, Takahashi S, Nomura T, Kouno M. A potential link between desmoglein 3 and epidermal growth factor receptor in oral squamous cell carcinoma and its effect on cetuximab treatment efficacy. Exp Dermatol 2019;28:614-7.

Huang CC, Lee TJ, Chang PH, Lee YS, Chuang CC, Jhang YJ, et al. Desmoglein 3 is overexpressed in inverted papilloma and squamous cell carcinoma of sinonasal cavity. Laryngoscope 2010;120:26-9.